
(AGENPARL) – SILVER SPRING mer 26 aprile 2023 FDA approves Vowst, the first orally administered fecal microbiota product. Vowst is approved for the prevention of recurrence of Clostridioides difficile infection in individuals 18 years of age and older, following completion of antibacterial treatment for recurrent CDI.
Fonte/Source: http://www.fda.gov/news-events/press-announcements/fda-approves-first-orally-administered-fecal-microbiota-product-prevention-recurrence-clostridioides